Cargando…
Association between genomic recurrence risk and well-being among breast cancer patients
BACKGROUND: Gene expression profiling (GEP) is increasingly used in the rapidly evolving field of personalized medicine. We sought to evaluate the association between GEP-assessed of breast cancer recurrence risk and patients’ well-being. METHODS: Participants were Dutch women from 10 hospitals bein...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2013
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3689597/ https://www.ncbi.nlm.nih.gov/pubmed/23777535 http://dx.doi.org/10.1186/1471-2407-13-295 |
_version_ | 1782274268851077120 |
---|---|
author | Retèl, Valesca P Groothuis-Oudshoorn, Catharina GM Aaronson, Neil K Brewer, Noel T Rutgers, Emiel JT van Harten, Wim H |
author_facet | Retèl, Valesca P Groothuis-Oudshoorn, Catharina GM Aaronson, Neil K Brewer, Noel T Rutgers, Emiel JT van Harten, Wim H |
author_sort | Retèl, Valesca P |
collection | PubMed |
description | BACKGROUND: Gene expression profiling (GEP) is increasingly used in the rapidly evolving field of personalized medicine. We sought to evaluate the association between GEP-assessed of breast cancer recurrence risk and patients’ well-being. METHODS: Participants were Dutch women from 10 hospitals being treated for early stage breast cancer who were enrolled in the MINDACT trial (Microarray In Node-negative and 1 to 3 positive lymph node Disease may Avoid ChemoTherapy). As part of the trial, they received a disease recurrence risk estimate based on a 70-gene signature and on standard clinical criteria as scored via a modified version of Adjuvant! Online. \Women completed a questionnaire 6–8 weeks after surgery and after their decision regarding adjuvant chemotherapy. The questionnaire assessed perceived understanding, knowledge, risk perception, satisfaction, distress, cancer worry and health-related quality of life (HRQoL), 6–8 weeks after surgery and decision regarding adjuvant chemotherapy. RESULTS: Women (n = 347, response rate 62%) reported high satisfaction with and a good understanding of the GEP information they received. Women with low risk estimates from both the standard and genomic tests reported the lowest distress levels. Distress was higher predominately among patients who had received high genomic risk estimates, who did not receive genomic risk estimates, or who received conflicting estimates based on genomic and clinical criteria. Cancer worry was highest for patients with higher risk perceptions and lower satisfaction. Patients with concordant high-risk profiles and those for whom such profiles were not available reported lower quality of life. CONCLUSION: Patients were generally satisfied with the information they received about recurrence risk based on genomic testing. Some types of genomic test results were associated with greater distress levels, but not with cancer worry or HRQoL. TRIAL REGISTRATION: ISRCTN: ISRCTN18543567 |
format | Online Article Text |
id | pubmed-3689597 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2013 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-36895972013-06-22 Association between genomic recurrence risk and well-being among breast cancer patients Retèl, Valesca P Groothuis-Oudshoorn, Catharina GM Aaronson, Neil K Brewer, Noel T Rutgers, Emiel JT van Harten, Wim H BMC Cancer Research Article BACKGROUND: Gene expression profiling (GEP) is increasingly used in the rapidly evolving field of personalized medicine. We sought to evaluate the association between GEP-assessed of breast cancer recurrence risk and patients’ well-being. METHODS: Participants were Dutch women from 10 hospitals being treated for early stage breast cancer who were enrolled in the MINDACT trial (Microarray In Node-negative and 1 to 3 positive lymph node Disease may Avoid ChemoTherapy). As part of the trial, they received a disease recurrence risk estimate based on a 70-gene signature and on standard clinical criteria as scored via a modified version of Adjuvant! Online. \Women completed a questionnaire 6–8 weeks after surgery and after their decision regarding adjuvant chemotherapy. The questionnaire assessed perceived understanding, knowledge, risk perception, satisfaction, distress, cancer worry and health-related quality of life (HRQoL), 6–8 weeks after surgery and decision regarding adjuvant chemotherapy. RESULTS: Women (n = 347, response rate 62%) reported high satisfaction with and a good understanding of the GEP information they received. Women with low risk estimates from both the standard and genomic tests reported the lowest distress levels. Distress was higher predominately among patients who had received high genomic risk estimates, who did not receive genomic risk estimates, or who received conflicting estimates based on genomic and clinical criteria. Cancer worry was highest for patients with higher risk perceptions and lower satisfaction. Patients with concordant high-risk profiles and those for whom such profiles were not available reported lower quality of life. CONCLUSION: Patients were generally satisfied with the information they received about recurrence risk based on genomic testing. Some types of genomic test results were associated with greater distress levels, but not with cancer worry or HRQoL. TRIAL REGISTRATION: ISRCTN: ISRCTN18543567 BioMed Central 2013-06-18 /pmc/articles/PMC3689597/ /pubmed/23777535 http://dx.doi.org/10.1186/1471-2407-13-295 Text en Copyright © 2013 Retèl et al.; licensee BioMed Central Ltd. http://creativecommons.org/licenses/by/2.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Research Article Retèl, Valesca P Groothuis-Oudshoorn, Catharina GM Aaronson, Neil K Brewer, Noel T Rutgers, Emiel JT van Harten, Wim H Association between genomic recurrence risk and well-being among breast cancer patients |
title | Association between genomic recurrence risk and well-being among breast cancer patients |
title_full | Association between genomic recurrence risk and well-being among breast cancer patients |
title_fullStr | Association between genomic recurrence risk and well-being among breast cancer patients |
title_full_unstemmed | Association between genomic recurrence risk and well-being among breast cancer patients |
title_short | Association between genomic recurrence risk and well-being among breast cancer patients |
title_sort | association between genomic recurrence risk and well-being among breast cancer patients |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3689597/ https://www.ncbi.nlm.nih.gov/pubmed/23777535 http://dx.doi.org/10.1186/1471-2407-13-295 |
work_keys_str_mv | AT retelvalescap associationbetweengenomicrecurrenceriskandwellbeingamongbreastcancerpatients AT groothuisoudshoorncatharinagm associationbetweengenomicrecurrenceriskandwellbeingamongbreastcancerpatients AT aaronsonneilk associationbetweengenomicrecurrenceriskandwellbeingamongbreastcancerpatients AT brewernoelt associationbetweengenomicrecurrenceriskandwellbeingamongbreastcancerpatients AT rutgersemieljt associationbetweengenomicrecurrenceriskandwellbeingamongbreastcancerpatients AT vanhartenwimh associationbetweengenomicrecurrenceriskandwellbeingamongbreastcancerpatients |